MarketPeel
Insider Trading Intelligence
Pricing
…
JC

Justin Chakma

SPRY
CHIEF BUSINESS OFFICER · ARS PHARMACEUTICALS, INC. · CIK 0001951238
FILING MIX · LIFETIME44%/56%
BUYS
18
SELLS
23
TOTAL VALUE
$8.97M
COMPANIES
1
ACTIVE SINCE
Nov 2022
HOLDINGS NOW
240,000
AVG SELL PX
$12.31
TRADE KIND
SHOWING 41 / 41
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
13 backtested trades · 8 horizons · 15 pending
Forward-return performance of every backtestable P/S trade by Justin Chakma, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d13+100.00%-9.29%-0.67%-8.62%-7.43%—
14d13+84.62%-10.40%-0.62%-9.77%-11.63%—
30d13+84.62%-13.05%-1.52%-11.53%-17.98%—
60d13+76.92%-0.57%+0.41%-0.99%-3.58%—
90d13+76.92%-14.70%-3.07%-11.63%-18.79%—
180d13+23.08%+5.58%+0.29%+5.29%+7.22%—
1y13(2 pending)+100.00%-27.57%+13.81%-41.38%-43.80%—
2y13(13 pending)——————
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
SPRY · 240,000 shares · as of Jan 2, 2026
087,500175,000262,500350,0002023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 18 buys / 23 sellsCOVERAGE · 14 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
240,000——240,000Jan 2, 2026Jan 5, 2026 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
Chief Business Officer
30,000$8.91$267.4K136,380Nov 12, 2025Nov 14, 2025 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
Chief Business Officer
30,000——89,047Nov 12, 2025Nov 14, 2025 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASE
Chief Business Officer
30,000$0.84$25.2K166,380Nov 12, 2025Nov 14, 2025 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
Chief Business Officer
136,380$8.86$1.21M0Nov 12, 2025Nov 14, 2025 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
274,100——274,100Jan 2, 2025Jan 3, 2025 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
Chief Business Officer
27,272——55,461Dec 13, 2024Dec 13, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
Chief Business Officer
27,272$12.06$329.0K136,380Dec 13, 2024Dec 13, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASE
Chief Business Officer
27,272$1.44$39.3K163,652Dec 13, 2024Dec 13, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
Chief Business Officer
117,333——119,047Dec 12, 2024Dec 13, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
Chief Business Officer
117,333$12.27$1.44M136,380Dec 12, 2024Dec 13, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASE
Chief Business Officer
117,333$0.84$98.6K253,713Dec 12, 2024Dec 13, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASE
Chief Business Officer
50,000$0.84$42.0K186,380Dec 10, 2024Dec 12, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
Chief Business Officer
50,000$13.15$657.6K136,380Dec 10, 2024Dec 12, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
Chief Business Officer
50,000——0Dec 10, 2024Dec 12, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASE
Chief Business Officer
50,000$0.84$42.0K186,380Dec 6, 2024Dec 6, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
Chief Business Officer
50,000$14.23$711.6K136,380Dec 6, 2024Dec 6, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
Chief Business Officer
50,000——50,000Dec 6, 2024Dec 6, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASE
Chief Business Officer
49,640$0.84$41.7K186,020Dec 5, 2024Dec 6, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
Chief Business Officer
49,640——100,000Dec 5, 2024Dec 6, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
Chief Business Officer
49,640$14.13$701.6K136,380Dec 5, 2024Dec 6, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
Chief Business Officer
45,000$13.95$627.9K136,380Dec 4, 2024Dec 6, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASE
Chief Business Officer
45,000$0.84$37.8K181,380Dec 4, 2024Dec 6, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
Chief Business Officer
45,000——149,640Dec 4, 2024Dec 6, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASE
Chief Business Officer
41,740$0.84$35.1K181,380Dec 3, 2024Dec 4, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
Chief Business Officer
41,740——194,640Dec 3, 2024Dec 4, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
Chief Business Officer
45,000$13.19$593.4K136,380Dec 3, 2024Dec 4, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
Chief Business Officer
3,260——0Dec 3, 2024Dec 4, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASE
Chief Business Officer
3,260$0.84$2.7K139,640Dec 3, 2024Dec 4, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASE
Chief Business Officer
45,000$0.84$37.8K181,380Dec 2, 2024Dec 4, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
Chief Business Officer
45,000——3,260Dec 2, 2024Dec 4, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
Chief Business Officer
45,000$13.67$615.2K136,380Dec 2, 2024Dec 4, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
Chief Business Officer
25,000$14.39$359.8K136,380Nov 27, 2024Nov 27, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
Chief Business Officer
42,186$14.05$592.6K161,380Nov 26, 2024Nov 27, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
Chief Business Officer
32,814$14.00$459.4K203,566Nov 25, 2024Nov 27, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
350,000——350,000Jan 2, 2024Jan 4, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
165,000——165,000Jan 3, 2023Jan 5, 2023 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
236,380——236,380Nov 8, 2022Nov 10, 2022 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
48,260——48,260Nov 8, 2022Nov 10, 2022 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
236,380——236,380Nov 8, 2022Nov 10, 2022 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
82,733——82,733Nov 8, 2022Nov 10, 2022 ↗View →
Other insiders · SPRY
Loading peer insiders…
About this filer
CIK 0001951238
ROLE
Chief Business Officer
PRIMARY
SPRY
COMPANIES
1
ACTIVE SINCE
Nov 2022
MARKETPEEL · /INSIDER/0001951238DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback